Trabectedin and its potential in the treatment of soft tissue sarcoma

References

• AntmanKCrowleyJBalcerzakSPAn intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomasJ Clin Oncol1993111276858315425
   PubMed Web of Science ®Google Scholar
• AntonescuCRTschernyavskySJDecusearaRPrognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 casesClin Cancer Res2001739778711751490
   PubMed Web of Science ®Google Scholar
• BayJORay-CoquardIFayetteJDocetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysisInt J Cancer20061197061116496406
   PubMed Web of Science ®Google Scholar
• BlayJYLeCAVerweijJScurrMA phase II study of ET-743/trabectedin (‘Yondelis’) for patients with advanced gastrointestinal stromal tumoursEur J Cancer20044013273115177491
   PubMed Web of Science ®Google Scholar
• ClarkMAFisherCJudsonISoft-tissue sarcomas in adultsN Engl J Med20053537011116107623
   PubMed Web of Science ®Google Scholar
• CohenRBSchilderRJChengJFinal results of a combination study between trabectedin and pegylatedASCO Meeting Abstracts2005233074
   Google Scholar
• CrozatAAmanPMandahlNFusion of CHOP to a novel RNA-binding protein in human myxoid liposarcomaNature199336364048510758
   PubMed Web of Science ®Google Scholar
• D’IncalciMColomboTUbezioPThe combination of yondelis and cisplatin is synergistic against human tumor xenograftsEur J Cancer2003391920612932672
   PubMed Web of Science ®Google Scholar
• David-CordonnierMHGajateCOlmeaODNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedinChem Biol20051212011016298299
   PubMed Web of Science ®Google Scholar
• DelalogeSYovineATaammaAEcteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients – preliminary evidence of activityJ Clin Oncol20011912485511230465
   PubMed Web of Science ®Google Scholar
• DonaldSVerschoyleRDGreavesPComplete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the ratCancer Res2003635902814522916
   PubMed Web of Science ®Google Scholar
• EdmonsonJHRyanLMBlumRHRandomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomasJ Clin Oncol1993111269758315424
   PubMed Web of Science ®Google Scholar
• FriedmanDHuZKolbEAEcteinascidin-743 inhibits activated but not constitutive transcriptionCancer Res20026233778112067978
   PubMed Web of Science ®Google Scholar
• Garcia-CarboneroRSupkoJGMakiRGEcteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic studyJ Clin Oncol20052354849216110008
   PubMed Web of Science ®Google Scholar
• Garcia-CarboneroRSupkoJGManolaJPhase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapyJ Clin Oncol20042214809015084621
   PubMed Web of Science ®Google Scholar
• GomezJLopez-LazaroLGuzmanCIdentification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743ASCO Meeting Abstracts200019727
   Google Scholar
• GoreLRiveraELavalleeKPhase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignanciesASCO Meeting Abstracts2006242079
   Google Scholar
• GrasselliGMalossiAColomboNPhase I and pharmacokinetic (PK) study of ecteinascidin-743 (ET, Trabectedin) and cisplatin (P) combination in pre-treated patients (pts) with selected advanced solid tumorsASCO Meeting Abstracts200722542
   Google Scholar
• GrossoFDemetriGDBlayJYPatterns of tumor response to trabectedin (ET743) in myxoid liposarcomasASCO Meeting Abstracts2006249511
   Google Scholar
• GrossoFDileoPSanfilippoRSteroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcomaEur J Cancer20064214849016737808
   PubMed Web of Science ®Google Scholar
• GrossoFForniCFrapolliRSensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcriptASCO Meeting Abstracts20072510000
   Google Scholar
• GrossoFJonesRLDemetriGDEfficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyLancet Oncol2007859560217586092
   PubMed Web of Science ®Google Scholar
• HensleyMLMakiRVenkatramanEGemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trialJ Clin Oncol20022028243112065559
   PubMed Web of Science ®Google Scholar
• HerreroABMartin-CastellanosCMarcoECross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedinCancer Res20066681556216912194
   PubMed Web of Science ®Google Scholar
• HuyghGClementPMDumezHEcteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patientsSarcoma200620065628217496996
   PubMedGoogle Scholar
• BlayJYJudsonIPhase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trialJ Clin Oncol2005235768415659504
   PubMed Web of Science ®Google Scholar
• MorganJALe CesneAChawlaSRandomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I)ASCO Meeting Abstracts20072510060
   Google Scholar
• PapadopoulosKPChuQPatnaikAPhase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumorsASCO Meeting Abstracts2006242029
   Google Scholar
• PatelSRGandhiVJenkinsJPhase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulationJ Clin Oncol2001193483911481354
   PubMed Web of Science ®Google Scholar
• RyanDPPuchalskiTSupkoJGA phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumorsOncologist20027531812490740
   PubMed Web of Science ®Google Scholar
• RyanDPSupkoJGEderJPPhase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignanciesClin Cancer Res200172314211234874
   PubMed Web of Science ®Google Scholar
• SamuelsBLRushingDChawlaSPRandomized phase II study of trabectedin (ET-743) given by twoASCO Meeting Abstracts2004229000
   Google Scholar
• SchoffskiPCasaliPGTaronMDNA repair functionality modulates the clinical outcome of patientsASCO Meeting Abstracts2006249522
   Google Scholar
• SoaresDGEscargueilAEPoindessousVFrom the cover: replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743Proc Natl Acad Sci USA200710413062717656556
   PubMed Web of Science ®Google Scholar
• TaammaAMissetJLRiofrioMPhase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumorsJ Clin Oncol20011912566511230466
   PubMed Web of Science ®Google Scholar
• TakahashiNLiWBanerjeeDSequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivoCancer Res20026269091512460906
   PubMed Web of Science ®Google Scholar
• TakahashiNLiWWBanerjeeDSequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cellsClin Cancer Res200173251711595721
   PubMed Web of Science ®Google Scholar
• TakebayashiYGoldwasserFUrasakiYEcteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expressionClin Cancer Res71859111205907
   PubMed Web of Science ®Google Scholar
• TakebayashiYPourquierPZimonjicDBAntiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repairNat Med200179616611479630
   PubMed Web of Science ®Google Scholar
• TwelvesCHoekmanKBowmanAPhase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumoursEur J Cancer20033918425112932661
   PubMed Web of Science ®Google Scholar
• Villalona-CaleroMAEckhardtSGWeissGA phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignanciesClin Cancer Res20028758511801542
   PubMed Web of Science ®Google Scholar
• Von MehrenMBuckDTemmerEPhase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignanciesASCO Meeting Abstracts2006242068
   Google Scholar
• WilsonREWoodWCLernerHLDoxorubicin chemotherapy in the treatment of soft-tissue sarcoma. Combined results of two randomized trialsArch Surg1986121135493535741
   PubMedGoogle Scholar
• YovineARiofrioMBlayJYPhase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patientsJ Clin Oncol200422890914990645
   PubMed Web of Science ®Google Scholar